Anyone know why trading of DNA is halted?
They reported earnings.$0.35 vs. estimate of $0.30.Big upside for Herceptin and Avastin vs. estimatesDownside for Rituxan and Tarceva vs. estimates.-chris
back in ahgood lucktr
+4 AH but expect some volatility during the conference call which you can listen to right now at this link if you want to:http://biz.yahoo.com/cc/3/60483.html
In the CC, they discuss the Cabilly patent issue. Revenues from the patent accounted for one cent per share of earnings in Q3 and would be approx. 4 cents per share in quarter. This represents the potential loss to DNA should the patent ruling eventually go against them.-chris